These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1884372)

  • 21. Placental isoferritin patterns during first-trimester intrauterine gestation.
    Maymon R; Bar J; Halperin R; Bukovsky I; Moroz C
    Gynecol Obstet Invest; 1996; 42(4):271-3. PubMed ID: 8979102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum neopterin levels in patients with breast cancer.
    Yildirim Y; Gunel N; Coskun U; Pasaoglu H; Aslan S; Cetin A
    Med Oncol; 2008; 25(4):403-7. PubMed ID: 18320364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of recurrent spontaneous abortions by immunization with paternal lymphocytes induces immunosuppression by placental isoferritin.
    Moroz C; Livni E; Segal J
    Am J Reprod Immunol; 1993 Aug; 30(1):32-6. PubMed ID: 8260021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of p43 in breast cancer tissue, correlation with prognostic parameters.
    Rosen HR; Moroz C; Reiner A; Stierer M; Svec J; Reinerova M; Schemper M; Jakesz R
    Cancer Lett; 1992 Oct; 67(1):35-45. PubMed ID: 1423243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placental isoferritin measured by a specific monoclonal antibody as a predictive marker for preterm contraction outcome.
    Maymon R; Bahari C; Moroz C
    Obstet Gynecol; 1989 Oct; 74(4):597-9. PubMed ID: 2797636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.
    Rosen HR; Moroz C; Reiner A; Reinerova M; Stierer M; Svec J; Schemper M; Jakesz R
    Breast Cancer Res Treat; 1992; 24(1):17-26. PubMed ID: 1463868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of placental isoferritin with birth weight and time point of first contractions.
    Rosen AC; Rosen HR; Huber K; Bauer K; Ausch C; Redlich K; Klein MJ; Moroz C
    Gynecol Obstet Invest; 1995; 39(1):11-4. PubMed ID: 7890246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.
    Capeller B; Caffier H; Sütterlin MW; Dietl J
    Anticancer Res; 2003; 23(2A):1011-5. PubMed ID: 12820340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double antibody radioimmunoassay for monitoring metastatic breast cancer.
    Schecter RL; Major PP; Kovac PE; Ishida M; Kovalik EC; Dion AS; Langleben A; Boileau G; Boos G; Panasci L
    Br J Cancer; 1988 Sep; 58(3):362-7. PubMed ID: 3179189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placental isoferritin-associated p43 in pregnancy and breast cancer. Minireview.
    Rosen HR
    Neoplasma; 1996; 43(6):357-62. PubMed ID: 8996558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placental isoferritin in gestational diabetes mellitus.
    Bar J; Hod M; Maymon R; Moroz C
    Acta Obstet Gynecol Scand; 1998 May; 77(5):504-7. PubMed ID: 9654171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.
    Tampellini M; Berruti A; Gerbino A; Buniva T; Torta M; Gorzegno G; Faggiuolo R; Cannone R; Farris A; Destefanis M; Moro G; Deltetto F; Dogliotti L
    Br J Cancer; 1997; 75(5):698-702. PubMed ID: 9043027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an immunoassay for all human isoferritins, and its application to serum ferritin evaluation.
    Cozzi A; Levi S; Bazzigaluppi E; Ruggeri G; Arosio P
    Clin Chim Acta; 1989 Oct; 184(3):197-206. PubMed ID: 2692876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.
    Isola JJ; Holli K; Oksa H; Teramoto Y; Kallioniemi OP
    Cancer; 1994 Feb; 73(3):652-8. PubMed ID: 7905363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
    Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
    Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
    Leitzel K; Teramoto Y; Sampson E; Mauceri J; Langton BC; Demers L; Podczaski E; Harvey H; Shambaugh S; Volas G
    J Clin Oncol; 1992 Sep; 10(9):1436-43. PubMed ID: 1355522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Detection of serum isoferritin level in 195 patients with cancer].
    Cai G; Wei L; Lü S; Hao D; Li Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):395-7. PubMed ID: 8732059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.